JHJames Edward Hudson

James Edward Hudson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


James Edward Hudson has a total of 492 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A transient modified mRNA encoding Myc and cyclin T1 improves cardiac function after myocardial injury

    by Aleksandra Boikova, Gregory A. Quaife-Ryan, Christopher A. P. Batho, Rowda Dahir, Henrietta Cserne Szappanos, Harley Robinson, Elsa Lawrence, Camilla Ascanelli, Jin Seok Lee, Kypros Kyprianou Kokonos, et al.

    Myc is an evolutionarily conserved transcription factor that is necessary for the restoration of tissues in multiple regenerative species. The adult mammalian heart lacks regenerative capacity and cardiomyocytes fail to divide following damage-induced signaling. Transgenic expression of Myc and cyclin T1 can drive substantial adult cardiomyocyte proliferation to replace lost cardiomyocytes. Here, using transgenic models and a prototypical mRNA therapeutic, we show that Myc and cyclin T1 require transient induction for cardiomyocyte proliferation that leads to myocardial repair and functional recovery after myocardial infarction in mice. This research provides a strategy to translate Myc–cyclin T1 coexpression for cardiac regeneration to address serious unmet needs in the treatment of cardiovascular disease.


  • Open Access

    Cardiopedia-Ligand: A ligand-receptor perturbation atlas of human cardiac organoid function and transcriptional state

    by Janice D. Reid, Simon R. Foster, Mary Lor, Alexander S. Hauser, Brendan Griffen, Rebecca L. Fitzsimmons, James E. Hudson


  • IGFBP2 Mediates Human iPSC-Cardiomyocyte Proliferation in a Cellular Contact-Dependent Manner

    by Soah Lee, Paul Heinrich, Daniel Lee, Yongwon Kang, Harley R. Robinson, Sean J. Humphrey, Jihye Yun, William R. Goodyer, Jan W. Buikema, David T. Paik, et al.

    BACKGROUND: Induction of cardiomyocyte proliferation in situ represents a promising strategy for myocardial regeneration following injury. However, cardiomyocytes possess intrinsic inhibitory mechanisms that attenuate pro-proliferative signaling and constrain their expansion. We hypothesized that cell–cell contact is a key suppressor of cardiomyocyte proliferation. We aimed to delineate the underlying molecular pathways to enable sustained proliferation in 3-dimensional contexts. METHODS: Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) were cultured at varying plating densities to examine the impact of cell-cell contact on cell cycle activity. Phosphoproteomic profiling was performed in sparse versus dense cultures to identify signaling alterations. Conditioned media from sparse cultures were interrogated using a human growth factor array to identify secreted pro-proliferative factors. RESULTS: hiPSC-CM proliferation increased proportionally with plating density until intercellular contacts were established, at which point proliferation was suppressed. Dense cultures exhibited enhanced adherens junction assembly, sarcomeric organization, and contractile function. Increased cell-cell contact in dense conditions attenuated nuclear translocation of β-catenin and reduced TCF/LEF (T cell factor/lymphoid enhancer factor family) transcriptional activity, providing a mechanistic basis for the reduced hiPSC-CM proliferation. Disruption of adherens junctions or sarcomere assembly via siRNA-mediated knockdown of N-cadherin or α-actinin, respectively, resulted in increased cell cycle activation of hiPSC-CMs, but this was not sufficient to drive division of hiPSC-CMs. Additional screening for putative secreted growth factors in the conditioned media from sparsely plated hiPSC-CMs revealed the enrichment of IGFBP2 (insulin-like growth factor-binding protein 2), which was sufficient to drive hiPSC-CM division in the presence of cell-cell contact in 3-dimensional constructs. CONCLUSIONS: Our findings demonstrate that cell-cell contact inhibits hiPSC-CM proliferation through adherens junction formation, sarcomeric assembly, and reduced IGFBP2 secretion. Importantly, exogenous supplementation of IGFBP2 can overcome cell contact-mediated inhibition of hiPSC-CM proliferation and facilitate the growth of 3-dimensional cardiac tissue. These insights provide valuable implications for advancing cardiac tissue engineering and regenerative therapies.


  • Open Access

    Endothelial specialization and angiocrine factors are critical for vascularized organoid models

    by Rebecca L. Fitzsimmons, James E. Hudson


  • Targeted glycophagy ATG8 therapy reverses diabetic heart disease in mice and in human engineered cardiac tissues

    by K. M. Mellor, U. Varma, P. Koutsifeli, C. L. Curl, J. V. Janssens, L. J. Daniels, G. B. Bernasochi, A. J. A. Raaijmakers, M. Annandale, X. Li, et al.

    Diabetic heart disease is highly prevalent and is associated with the early development of impaired diastolic relaxation. The mechanisms of diabetic heart disease are poorly understood, and it is a condition for which there are no targeted therapies. Recently, disrupted glycogen autophagy (glycophagy) and glycogen accumulation have been identified in the diabetic heart. Glycophagy involves glycogen receptor binding and linking with an ATG8 protein to locate and degrade glycogen within an intracellular phagolysosome. Here we show that glycogen receptor protein starch binding domain protein 1 (STBD1) is mobilized early in the cardiac glycogen response to metabolic challenge in vivo, and that deficiency of a specific ATG8 family protein, γ-aminobutyric acid type A receptor-associated protein-like 1 (GABARAPL1), is associated with diastolic dysfunction in diabetes. Gabarapl1 gene delivery treatment remediated cardiomyocyte and cardiac diastolic dysfunction in type 2 diabetic mice and the diastolic performance of ‘diabetic’ human induced pluripotent stem cell-derived cardiac organoids. We identify glycophagy dysregulation as a mechanism and potential treatment target for diabetic heart disease.


  • Open Access

    Using modified mRNA for cardiomyocyte proliferation and cardiac genetic disease modelling and treatment

    by Christopher A.P. Batho, James E. Hudson, Catherine H. Wilson

    Heart failure (HF) is a leading cause of death worldwide and the associated mortality and socioeconomic burden is predicted to worsen. Current therapies for HF focus on managing the causes and symptoms; however, these current treatment options are unable to reverse heart muscle degeneration, with heart transplantation the only cure. The ability to re-muscularise the heart represents a significant unmet clinical need. Although numerous biological pathways driving re-muscularisation have been identified, delivery of therapeutic factors is challenging. Modified mRNA (modRNA) is synthetic mRNA with greater gene packaging capacity, low immunogenic response and allows transient but robust protein expression. In this mini-review, we highlight the emerging discoveries surrounding the application of modRNA in the cardiovascular field. Specifically, we focus on different examples illustrating how modRNA delivery post-myocardial infarction can drive cardiomyocyte proliferation and achieve cardiac regeneration. In addition, we demonstrate how modRNA is being used for protein replacement and Cas delivery for both modelling and therapeutic studies focussed on genetic cardiac diseases. For these applications, in particular Cas delivery, the transient nature of modRNA overexpression is a beneficial property with reduced side effects compared with other modalities. Finally, we preview some of the roadblocks limiting the clinical translation of modRNA and avenues being explored to overcome these. In summary, the flexibility of modRNA combined with its improved safety profile provides a gene overexpression tool capable of integration into all steps of the preclinical and clinical therapeutic pipeline enabling the discovery of improved treatments for HF.


  • Open Access

    Maturation of human cardiac organoids enables complex disease modeling and drug discovery

    by Mark W. Pocock, Janice D. Reid, Harley R. Robinson, Natalie Charitakis, James R. Krycer, Simon R. Foster, Rebecca L. Fitzsimmons, Mary Lor, Lynn A. C. Devilée, Christopher A. P. Batho, et al.

    Maturation of human pluripotent stem (hPS) cell-derived cardiomyocytes is critical for their use as a model system. Here we mimic human heart maturation pathways in the setting of hPS cell-derived cardiac organoids (hCOs). Specifically, transient activation of 5′ AMP-activated protein kinase and estrogen-related receptor enhanced cardiomyocyte maturation, inducing expression of mature sarcomeric and oxidative phosphorylation proteins, and increasing metabolic capacity. hCOs generated using the directed maturation protocol (DM-hCOs) recapitulate cardiac drug responses and, when derived from calsequestrin 2 (CASQ2) and ryanodine receptor 2 (RYR2) mutant hPS cells exhibit a pro-arrhythmia phenotype. These DM-hCOs also comprise multiple cell types, which we characterize and benchmark to the human heart. Modeling of cardiomyopathy caused by a desmoplakin (DSP) mutation resulted in fibrosis and cardiac dysfunction and led to identifying the bromodomain and extra-terminal inhibitor INCB054329 as a drug mitigating the desmoplakin-related functional defect. These findings establish DM-hCOs as a versatile platform for applications in cardiac biology, disease and drug screening.


  • Open Access

    Macrophage Containing Cardiac Organoids for Studying Inflammatory Programmes Driving Cardiovascular Disease

    by Christopher R. Hunter, James E. Hudson

    Purpose of Review There are specialised heart populations of macrophages that arise from diverse origins in vivo. Incorporating these into human pluripotent derived cardiac organoids (hCOs) provides a new method to study their role in cardiac function and disease. Herein, we review this topic and propose future directions. Recent Findings Macrophages are particularly important and exert positive and negative influences during the pathogenesis of disease, and resolution after injury. The heart microenvironment imprints specific functions into cardiac macrophages including efferocytosis of mitochrondria, control of electrical conduction and control of stromal and parenchymal homeostasis in the heart. Initial studies using hCOs has shown that incorporating macrophages improves maturation and disease modelling. Summary We highlight key in vivo functions have been shown by macrophages in hCOs. However, outstanding questions remain and represent exciting research avenues in the future. An important avenue being incorporation of the macrophage phenotypic diversity recently shown in vivo.


  • Open Access

    Muscle-specific Ryanodine receptor 1 properties underlie limb-girdle muscular dystrophy 2B/R2 progression

    by Aldo Meizoso-Huesca, Cedric R. Lamboley, James R. Krycer, Mark P. Hodson, James E. Hudson, Bradley S. Launikonis

    Ryanodine receptor 1 Ca2+ leak is a signal in skeletal muscle, but chronic leak can underlie pathology. Here we show that in healthy male mouse, limb-girdle muscle presents higher sympathetic input, elevated ryanodine receptor 1 basal phosphorylation, Ca2+ leak and mitochondrial Ca2+ content compared to distal leg muscles. These regional differences are consistent with heat generation in resting muscle to maintain core temperature. The dysferlin-null mouse develops severe pathology in the limb-girdle but not leg muscles. Absence of dysferlin disrupts dihydropyridine receptors’ inhibitory control over ryanodine receptor 1 leak, synergistically increasing leak through the already phosphorylated channel of limb-girdle muscle. This alters Ca2+ handling and distribution leading to reactive oxygen species production prior to disease onset. With age, oxidation of Ca2+ -handling proteins in dysferlin-null limb-girdle muscle alters basal Ca2+ movements. Our results show that muscle-specific pathology in dysferlin-null mice is linked to increased ryanodine receptor 1 Ca2+ leak.